Healthcare Giants NVO & LLY Eye Trillion-Dollar Club

The Government Pension Fund Global predicts that $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ could be the first healthcare companies to reach trillion-dollar club, benefiting from the rising demand for diabetes and weight-loss drugs.

With less than 1% of overweight individuals currently receiving treatment, the potential market for these drugs remains vast.

$Novo-Nordisk A/S(NVO)$'s strong earnings, driven by the success of its drug Wegovy, pushed its market value to $511.29 bln.

While $Eli Lilly(LLY)$’s market capitalization stands at around $612 bln.

The Government Pension Fund Global holds significant stakes in both companies and sees promising opportunities for their drugs beyond weight loss, potentially addressing conditions like chronic kidney disease and Alzheimer's.

If these forecasts hold true, Novo Nordisk and Eli Lilly could join the ranks of trillion-dollar healthcare giants, akin to tech companies like Microsoft and Apple.

Time to invest in weight-loss companies?

Weight-loss companies continue to hit records. LLY hits new record of $613; NOV reaches new high of $102 and its market value ranks first in European companies. -------------------- Are you bullish on the weight-loss drug companies? Time to invest or not as they continue to hit new highs? Will weight-loss drugs really impact the shopping demand as Walmart warns?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

tothehill
02-01
tothehill
Hilarious market potential! 😂 Agree! 🙌
KSR
02-02
KSR
👍

Leave a comment

472

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":269377699418120,"tweetId":"269377699418120","gmtCreate":1706790651828,"gmtModify":1707122633500,"author":{"id":3527667668165440,"authorId":3527667668165440,"authorIdStr":"3527667668165440","name":"Capital_Insights","avatar":"https://static.tigerbbs.com/cfdc66fff48bb2b9e2d328ac5eb33100","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[{"themeId":"3ba18faeb8364f42b810a81bee429b4d","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"Time to invest in weight-loss companies?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":3ba18faeb8364f42b810a81bee429b4d}&rnconfig={\"headerBarHidden\": true}","description":"Weight-loss companies continue to hit records. LLY hits new record of $613; NOV reaches new high of $102 and its market value ranks first in European companies.\n--------------------\nAre you bullish on the weight-loss drug companies?\nTime to invest or not as they continue to hit new highs?\nWill weight-loss drugs really impact the shopping demand as Walmart warns?","image":"https://community-static.tradeup.com/news/96ede51e656d3728375f75b1fee3f8e4"}],"images":[{"img":"https://community-static.tradeup.com/news/5d7a758ba9b42553dfa4c4a186caf25e","width":"1540","height":"705"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/5d7a758ba9b42553dfa4c4a186caf25e","width":"1540","height":"705"}],"title":"Healthcare Giants NVO & LLY Eye Trillion-Dollar Club","html":"<html><head></head><body>The Government Pension Fund Global predicts that <a data-mention-id=\"NVO\" class=\"teditor-mention\" data-mention-name=\"Novo-Nordisk A/S\" href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> and <a data-mention-id=\"LLY\" class=\"teditor-mention\" data-mention-name=\"Eli Lilly\" href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> could be the first healthcare companies to reach trillion-dollar club, benefiting from the rising demand for diabetes and weight-loss drugs. <img src=\"https://community-static.tradeup.com/news/5d7a758ba9b42553dfa4c4a186caf25e\" tg-width=\"1540\" tg-height=\"705\">With less than 1% of overweight individuals currently receiving treatment, the potential market for these drugs remains vast. <blockquote> <a data-mention-id=\"NVO\" class=\"teditor-mention\" data-mention-name=\"Novo-Nordisk A/S\" href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a>'s strong earnings, driven by the success of its drug Wegovy, pushed its market value to $511.29 bln.</blockquote><blockquote>While <a data-mention-id=\"LLY\" class=\"teditor-mention\" data-mention-name=\"Eli Lilly\" href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a>’s market capitalization stands at around $612 bln. </blockquote>The Government Pension Fund Global holds significant stakes in both companies and sees promising opportunities for their drugs beyond weight loss, potentially addressing conditions like chronic kidney disease and Alzheimer's. If these forecasts hold true, Novo Nordisk and Eli Lilly could join the ranks of trillion-dollar healthcare giants, akin to tech companies like Microsoft and Apple. </body></html>","htmlText":"<html><head></head><body>The Government Pension Fund Global predicts that <a data-mention-id=\"NVO\" class=\"teditor-mention\" data-mention-name=\"Novo-Nordisk A/S\" href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> and <a data-mention-id=\"LLY\" class=\"teditor-mention\" data-mention-name=\"Eli Lilly\" href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> could be the first healthcare companies to reach trillion-dollar club, benefiting from the rising demand for diabetes and weight-loss drugs. <img src=\"https://community-static.tradeup.com/news/5d7a758ba9b42553dfa4c4a186caf25e\" tg-width=\"1540\" tg-height=\"705\">With less than 1% of overweight individuals currently receiving treatment, the potential market for these drugs remains vast. <blockquote> <a data-mention-id=\"NVO\" class=\"teditor-mention\" data-mention-name=\"Novo-Nordisk A/S\" href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a>'s strong earnings, driven by the success of its drug Wegovy, pushed its market value to $511.29 bln.</blockquote><blockquote>While <a data-mention-id=\"LLY\" class=\"teditor-mention\" data-mention-name=\"Eli Lilly\" href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a>’s market capitalization stands at around $612 bln. </blockquote>The Government Pension Fund Global holds significant stakes in both companies and sees promising opportunities for their drugs beyond weight loss, potentially addressing conditions like chronic kidney disease and Alzheimer's. If these forecasts hold true, Novo Nordisk and Eli Lilly could join the ranks of trillion-dollar healthcare giants, akin to tech companies like Microsoft and Apple. </body></html>","text":"The Government Pension Fund Global predicts that $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ could be the first healthcare companies to reach trillion-dollar club, benefiting from the rising demand for diabetes and weight-loss drugs. With less than 1% of overweight individuals currently receiving treatment, the potential market for these drugs remains vast. $Novo-Nordisk A/S(NVO)$'s strong earnings, driven by the success of its drug Wegovy, pushed its market value to $511.29 bln. While $Eli Lilly(LLY)$’s market capitalization stands at around $612 bln. The Government Pension Fund Global holds significant stakes in both companies and sees promising opportunities for their drugs beyond weight loss, potentially addressing conditions like chronic kidney disease and Alzheimer's. If these forecasts hold true, Novo Nordisk and Eli Lilly could join the ranks of trillion-dollar healthcare giants, akin to tech companies like Microsoft and Apple.","highlighted":1,"essential":2,"paper":2,"likeSize":472,"commentSize":2,"repostSize":72,"favoriteSize":0,"link":"https://ttm.financial/post/269377699418120","repostId":0,"isVote":1,"tweetType":1,"viewCount":2550,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVO","LLY"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":816,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":269410834292816,"gmtCreate":1706790970325,"gmtModify":1706855090828,"authorId":3479274781763777,"author":{"id":3479274781763777,"authorId":3479274781763777,"name":"tothehill","avatar":"https://static.laohu8.com/picture118","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":269377699418120,"type":1,"supId":0,"prevId":0,"content":"Hilarious market potential! 😂 Agree! 🙌","text":"Hilarious market potential! 😂 Agree! 🙌","html":"Hilarious market potential! 😂 Agree! 🙌","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":269602863333560,"gmtCreate":1706837998989,"gmtModify":1706838011388,"authorId":4121076730674632,"author":{"id":4121076730674632,"authorId":4121076730674632,"name":"KSR","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":269377699418120,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/269377699418120"}